Interleukin-8 (CXCL8) in tumor associated non-vascular extracellular fluids: Its diagnostic and prognostic values. A review

International Journal of Biological Markers

Volumn 27, Issue 3, 2012, Pages

  Kotyza, Jaromír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cytokines; Interleukin 8; Oncology; Tumor markers

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR ALPHA; GLUCOSE 6 PHOSPHATE ISOMERASE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; STAT3 PROTEIN; TUMOR NECROSIS FACTOR;

ACTIN FILAMENT; ANGIOGENESIS; ASCITES FLUID; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHONDROBLASTOMA; CYST FLUID; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DRUG TARGETING; EXTRACELLULAR FLUID; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; INTERSTITIAL FLUID; INTRACELLULAR SIGNALING; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; KIDNEY POLYCYSTIC DISEASE; LUNG CANCER; MENINGEAL METASTASIS; MESOTHELIOMA; METASTASIS; MICRODIALYSIS; NEUTROPHIL; NONHODGKIN LYMPHOMA; PLEURA CAVITY; PLEURA EFFUSION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW; SALIVA LEVEL; THORACOSCOPY; TRANSCRIPTION REGULATION; TUMOR BIOPSY; TUMOR GROWTH; URINALYSIS; UTERINE CERVIX CANCER; VAGINAL SECRETION;

EXTRACELLULAR FLUID; HUMANS; INTERLEUKIN-8; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867559475     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9261     Document Type: Review

References (87)

1. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest 1989; 84: 1045-9.
2. Baggiolini M, Moser B, Clark-Lewis I. Interleukin-8 and related chemotactic cytokines. The Giles Filley Lecture. Chest 1994; 105: 95S-98S.
3. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunol Today 2000; 21: 418-20.
4. Feijoo E, Alfaro C, Mazzolini G, et al. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer 2005; 116: 275-81.
5. Stillie R, Farooq SM, Gordon JR, Stadnyk AW. The functional significance behind expressing two IL-8 receptor types on PMN. J Leukoc Biol 2009; 86: 529-43.
6. Schraufstatter IU, Trieu K, Zhao M, et al. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol 2003; 171: 6714-22.
7. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 2005; 7: 122-33.
8. Colombo MP, Maccalli C, Mattei S, Melani C, Radrizzani M, Parmiani G. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 1992; 2: 181-9.
9. Schadendorf D, Möller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151: 2667-75.
10. Norgauer J, Metzner B, Schraufstätter I. Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol 1996; 156: 1132-7.
11. Freund A, Chauveau C, Brouillet JP, et al. IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 2003; 22: 256-65.
12. Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 2000; 275: 6868-75.
13. Wigmore SJ, Fearon KC, Maingay JP, Lai PB, Ross JA. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol 1997; 273: E720-E726.
14. Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett 1992; 307: 97-101.
15. Kasahara T, Mukaida N, Yamashita K, Yagisawa H, Akahoshi T, Matsushima K. IL-1 and TNF-alpha induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology 1991; 74: 60-7.
16. Aihara M, Tsuchimoto D, Takizawa H, et al. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect Immun 1997; 65: 3218-24.
17. Hobbie S, Chen LM, Davis RJ, Galán JE. Involvement of mitogen-activated protein kinase pathways in the nuclear responses and cytokine production induced by Salmonella typhimurium in cultured intestinal epithelial cells. J Immunol 1997; 159: 5550-9.
18. DeForge LE, Preston AM, Takeuchi E, Kenney J, Boxer LA, Remick DG. Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem 1993; 268: 25568-76.
19. Sonoda Y, Kasahara T, Yamaguchi Y, Kuno K, Matsushima K, Mukaida N. Stimulation of interleukin-8 production by okadaic acid and vanadate in a human promyelocyte cell line, an HL-60 subline. Possible role of mitogen-activated protein kinase on the okadaic acid-induced NF-kappaB activation. J Biol Chem 1997; 272: 15366-72.
20. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leuko Biol 2002; 72: 847-55.
21. Roebuck KA, Carpenter LR, Lakshminarayanan V, Page SM, Moy JN, Thomas LL. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. J Leukoc Biol 1999; 65: 291-8.
22. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ. Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54: 3242-7.
23. Haim K, Weitzenfeld P, Meshel T, Ben-Baruch A. Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Neoplasia 2011; 13: 230-43.
24. Liotta LA, Mandler R, Murano G, et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986; 83: 3302-6.
25. Araki K, Shimura T, Yajima T, et al. Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem 2009; 284: 32305-11.
26. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-58.
27. Ancrile BB, ÓHayer KM, Counter CM. Oncogenic Ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interventions 2008; 8: 22-7.
28. Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
29. Wang JM, Taraboletti G, Matsushima K, Van Damme J, Mantovani A. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun 1990; 169: 165-70.
30. Petreaca ML, Yao M, Liu Y, DeFea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 2007; 18: 5014-23.
31. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest 2006; 24: 492-6.
32. Lokshin AE, Winans M, Landsittel D, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006; 102: 244-51.
33. Benoy IH, Salgado R, Van Dam P, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004; 10: 7157-62.
34. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12: 1175-81.
35. Alexandrakis MG, Coulocheri SA, Bouros D, Eliopoulos GD. Evaluation of ferritin, interleukin-6, interleukin-8 and tumor necrosis factor alpha in the differentiation of exudates and transudates in pleural effusions. Anticancer Res 1999; 19: 3607-12.
36. Ivarsson K, Runesson E, Sundtfeldt K, et al. The chemotactic cytokine interleukin-8-a cyst fluid marker for malignant epithelial ovarian cancer? Gynecol Oncology 1998; 71: 420-3.
37. Lee HL, Eom H-S, Yun T, et al. Serum and urine levels of interleukin-8 in patients with non-Hodgkińs lymphoma. Cytokine 2008; 43: 71-5.
38. Dennebaum R. Extravascular body fluids. In: Thomas L Ed. Clinical laboratory diagnostics. Frankfurt: TH-Books Verlagsgesellschaft mbH, 1998; 1327-75.
39. Olopade OI, Ultmann JE. Malignant effusions. Cancer J Clin 1991; 41: 166-79.
40. Abe T, Sakamoto K, Kamohara H, Hirano Y, Kuwahara N, Ogawa M. Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int I Cancer 1997; 74: 245-50.
41. Alexandrakis MG, Coulocheri SA, Bouros D, Mandalaki K, Karkavitsas N, Eliopoulos GD. Evaluation of inflammatory cytokines in malignant and benign pleural effusions. Oncol Rep 2000; 7: 1327-32.
42. Hoheisel G, Izbicki G, Roth M, et al. Proinflammatory cytokine levels in patients with lung cancer and carcinomatous pleurisy. Respiration 1998; 65: 183-6.
43. Hsu I-L, Su W-C, Yan J-J, Chang J-M, Lai W-W. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlation with patient survival and pleural effusion control. Lung Cancer 2009; 65: 371-6.
44. Kotyza J, Havel D, Vrzalová J, Kulda V, Pešek M. Diagnostic and prognostic significance of inflammatory markers in lung cancer associated pleural effusions. Int J Biol Markers 2010; 25: 12-20.
45. Pace E, Gjomarkaj M, Melis M, et al. Interleukin-8 induces lymphocyte chemotaxis into the pleural space. Role of pleural macrophages. Am J Respir Crit Care Med 1999; 159: 1592-9.
46. Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. Oncol Res 1999; 11: 187-94.
47. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 59: 367-71.
48. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000; 10: 33-41.
49. Alexandrakis MG, Moschandrea J, Kyriakou DS, Alexandraki R, Kouroumalis E. Use of a variety of biological parameters in distinguishing cirrhotic from malignant ascites. Int J Biol Markers 2001; 16: 45-49.
50. Radke J, Schmidt D, Bohme M, Schmidt U, Weise W, Morenz J. Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd 1996; 56: 83-7.
51. Nowak M, Glowacka E, Szoakowski M, et al. Proinflammatory and immunosupressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010; 31: 375-83.
52. Davidson B, Reich R, Kopolovic J, et al. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clinical Exp Metastasis 2002; 19: 135-44.
53. Olszewski WL, Kubicka U, Tarnowsi W, Bielecki K, Wesolowska A. Activation of human peritoneal immune cells in early stages of gastric and colon cancer. Surgery 2007; 141: 212-21.
54. Hillegass JM, Shukla A, Lathrop SA, et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 2010; 1203: 7-14.
55. Abramov Y, Anteby SO, Fasouliotis SJ, Barak V. The role of inflammatory cytokines in Meiǵs syndrome. Obstet Gynecol 2002; 99: 917-9.
56. Arici A. Local cytokines in endometrial tissue: the role of interleukin-8 in the pathogenesis of endometriosis. Ann N Y Acad Sci 2002; 955: 396-406.
57. Darai E, Detechev R, Hugol D, Quang NT. Serum and cyst fluid levels of interleukin (IL)-6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and Kotyza malignant cystic ovarian tumours. Human Reproduction 2003; 18: 1681-5.
58. Fasciani A, D́Ambrogio G, Bocci G, Luisi S, Artini PG, Genazzani AR. Vascular endothelial growth factor and interleukin-8 in ovarian cystic pathology. Fertil Steril 2001; 75: 1218-21.
59. Bussom S, Saif MW. Itraductal papillary mucinous neoplasia (IPMN). Highlights from "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP J Pancreas (online) 2010; 11: 131-4.
60. Uchikawa C, Shinozaki T, Nakajima T, Tkagishi K. Cytokine synthesis by chondroblastoma: relation to local inflammation. J Orthopaedic Surgery 2009; 17: 56-61.
61. Van Meir E, Ceska M, Effenberger F, et al. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res 1992; 52: 4297-305.
62. Fasciani A, D́Ambrogio G, Bocci G, Monti M, Genazzani AR, Artini PG. High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata. Molec Human Reproduction 2000; 6: 50-4.
63. Amura C, Brodsky K, Gitomer B, et al. CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol Cell Physiol 2008; 294: C786-C796.
64. Schwartz N, Michaelson JS, Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci 2007; 1109: 265-74.
65. Lisowska-Myjak B. Serum and urinary biomarkers of acute kidney injury. Blood Purif 2010; 29: 357-65.
66. Sheryka E, Wheeler MA, Hausladen DA, Weiss RM. Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma. Urology 2003; 62: 162-6.
67. Margel D, Pesvner-Fischer M, Baniel J, Yossepowitch O, Cohen IR. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urology 2011; 59: 113-9.
68. Kocak H, Oner-Iyidogan Y, Kocak T, Oner P. Determination and prognostic values of urinary interleukin-8, tumor necrosis factor-alpha, and leukocyte arylsulfatase-A activity in patients with bladder cancer. Clin Bioch 2004; 37: 673-8.
69. Shichkin VP, Lon AD, Yugrinova LD, et al. TNF receptor p55 and IL-8(72) and IL-8(77) isoforms: blood and urine levels in breast cancer patients. J Immunotoxicol 2009; 6: 235-42.
70. Wong DT. Towards a simple, saliva-based test for the detection of oral cancer. Expert Rev Mol Diagn 2006; 6: 267-72.
71. Yeh CK, Christodoulides NJ, Floriano PN, et al. Current development of saliva/oral fluid-based diagnostics. Tex Dent J 2010; 127: 651-61.
72. St John AR, Li Y, Zhou X, et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 929-35.
73. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005; 29: 42-5.
74. Korostoff A, Reder L, Masood R, Sinha UK. The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol 2011; 47: 282-7.
75. Li Y, St John MA, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004; 10: 8442-50.
76. Felgenhauer K. Laboratory diagnosis of neurological diseases. In: Thomas L ed. Clinical laboratory diagnostics. Frankfurt: TH-Books Verlagsgesellschaft mbH, 1998; 1308-26.
77. Brandsma D, Voest EE, de Jager W, et al. CSF protein profiling using Multiplex Immuno-assay. J Neurol 2006; 253: 1177-84.
78. Brandsma D, Taphoorn MJ, de Jager W, et al. Interleukin-8 CSF levels predict survival in patients with leptomeningeal metastases. Neurology 2006; 66: 243-6.
79. Marcus HJ, Carpenter KLH, Price SJ, Hutchinson PJ. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 2010; 97: 11-23.
80. Sun DZ, Ju DW, He J, et al. Tumor interstitial fluid and postoperative recurrence of tumors: an experimental study for verifying hypothesis of "tumor-phlegm microenvironment". Chin J Integr Med 2010; 16: 435-41.
81. Celis JE, Gromov P, Cabezon T, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment. Mol Cellular Proteomics 2004; 3: 327-44.
82. Tjiong MY, van der Vange N, ten Kate FJW, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecologic Oncology 1999; 73: 285-91.
83. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
84. Futakuchi M, Ogawa K, Tamano S, Takahashi S, Shirai T. Suppression of metastasis by nuclear factor kappaB inhibitors in an in vivo lung metastasis model of chemically induced hepatocellular carcinoma. Cancer Sci 2004; 95: 18-24.
85. Sun H, Chung W-C, Ryu S-H, et al. Cyclic AMP-responsive element binding protein-and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res 2008; 1: 316-28.
86. Zhu YM, Webster SJ, Flower D, Woll PJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer. British J Cancer 2004; 91: 1970-6.
87. Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010; 120: 485-97.